Reply: Is it not timely to consider how to balance cardiorenometabolic benefits and risks of statins?

Ahmed Tawakol; Hamed Emami; Michael Farkouh; Zahi A. Fayad; Kenneth Fifer; James H.F. Rudd; Sharath Subramanian; Thomas Van Dyke

doi:10.1016/j.jacc.2014.03.038

Reply: Is it not timely to consider how to balance cardiorenometabolic benefits and risks of statins?

Ahmed Tawakol
, Hamed Emami
, Michael Farkouh
, Zahi A. Fayad
, Kenneth Fifer
, James H.F. Rudd
, Sharath Subramanian
, Thomas Van Dyke

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	2881-2882
Number of pages	2
Journal	Journal of the American College of Cardiology
Volume	63
Issue number	25 PART A
DOIs	https://doi.org/10.1016/j.jacc.2014.03.038
State	Published - 1 Jul 2014

Access to Document

10.1016/j.jacc.2014.03.038

Cite this

@article{410da7ff2914427ebd29ca32592cac58,

title = "Reply: Is it not timely to consider how to balance cardiorenometabolic benefits and risks of statins?",

author = "Ahmed Tawakol and Hamed Emami and Michael Farkouh and Fayad, \{Zahi A.\} and Kenneth Fifer and Rudd, \{James H.F.\} and Sharath Subramanian and \{Van Dyke\}, Thomas",

note = "Funding Information: Please note: Merck \& Co., Inc. provided funding for the original study. Drs. Tawakol and Fayad received consulting fees and their institutions received grants from Roche and Merck Sharp \& Dohme Corp. , a subsidiary of Merck \& Co., Inc. Dr. Farkouh's institution received grants from Merck Sharp \& Dohme Corp . Dr. Rudd is supported by the NIHR Cambridge Biomedical Research Centre . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2014",

month = jul,

day = "1",

doi = "10.1016/j.jacc.2014.03.038",

language = "English",

volume = "63",

pages = "2881--2882",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "25 PART A",

}

TY - JOUR

T1 - Reply

T2 - Is it not timely to consider how to balance cardiorenometabolic benefits and risks of statins?

AU - Tawakol, Ahmed

AU - Emami, Hamed

AU - Farkouh, Michael

AU - Fayad, Zahi A.

AU - Fifer, Kenneth

AU - Rudd, James H.F.

AU - Subramanian, Sharath

AU - Van Dyke, Thomas

N1 - Funding Information: Please note: Merck & Co., Inc. provided funding for the original study. Drs. Tawakol and Fayad received consulting fees and their institutions received grants from Roche and Merck Sharp & Dohme Corp. , a subsidiary of Merck & Co., Inc. Dr. Farkouh's institution received grants from Merck Sharp & Dohme Corp . Dr. Rudd is supported by the NIHR Cambridge Biomedical Research Centre . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2014/7/1

Y1 - 2014/7/1

UR - https://www.scopus.com/pages/publications/84903218660

U2 - 10.1016/j.jacc.2014.03.038

DO - 10.1016/j.jacc.2014.03.038

M3 - Letter

C2 - 24794123

AN - SCOPUS:84903218660

SN - 0735-1097

VL - 63

SP - 2881

EP - 2882

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 25 PART A

ER -